Anuradha Paranjape
Overview
Explore the profile of Anuradha Paranjape including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hai A, Weiner M, Livshits A, Brown J, Paranjape A, Hwang W, et al.
Artif Intell Med
. 2024 Nov;
158:103010.
PMID: 39556977
A prediction model to assess the risk of hospital readmission can be valuable to identify patients who may benefit from extra care. Developing hospital-specific readmission risk prediction models using local...
2.
Razzaghi H, Forrest C, Hirabayashi K, Wu Q, Allen A, Rao S, et al.
Pediatrics
. 2024 Jan;
153(4).
PMID: 38225804
Objectives: Vaccination reduces the risk of acute coronavirus disease 2019 (COVID-19) in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against...
3.
Behari J, Bradley A, Townsend K, Becich M, Cappella N, Chuang C, et al.
Dig Dis Sci
. 2023 Dec;
69(2):370-383.
PMID: 38060170
Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are highly prevalent but underdiagnosed. Aims: We used an electronic health record data network to test a population-level risk stratification...
4.
Jackson S, Woodruff R, Nagavedu K, Fearrington J, Rolka D, Twentyman E, et al.
J Am Heart Assoc
. 2023 Oct;
12(21):e030240.
PMID: 37850404
Background Hypertension and diabetes are associated with increased COVID-19 severity. The association between level of control of these conditions and COVID-19 severity is less well understood. Methods and Results This...
5.
Razzaghi H, Forrest C, Hirabayashi K, Wu Q, Allen A, Rao S, et al.
medRxiv
. 2023 Oct;
PMID: 37808803
Objective: Vaccination reduces the risk of acute COVID-19 in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in...
6.
Deep Learning vs Traditional Models for Predicting Hospital Readmission among Patients with Diabetes
Hai A, Weiner M, Paranjape A, Livshits A, Brown J, Obradovic Z, et al.
AMIA Annu Symp Proc
. 2023 May;
2022:512-521.
PMID: 37128461
A hospital readmission risk prediction tool for patients with diabetes based on electronic health record (EHR) data is needed. The optimal modeling approach, however, is unclear. In 2,836,569 encounters of...
7.
Kelsey M, Mulder H, Chiswell K, Lampron Z, Nilles E, Kulinski J, et al.
Am J Prev Cardiol
. 2023 Apr;
14:100478.
PMID: 37025553
Objective: Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease, yet little is known about Lp(a) testing patterns in real-world practice. The objective of this analysis was to determine how...
8.
Jackson S, Block J, Rolka D, Pavkov M, Chevinsky J, Lekiachvili A, et al.
AJPM Focus
. 2023 Mar;
1(1):100012.
PMID: 36942020
Introduction: Hypertension and diabetes are associated with increased COVID-19 severity, yet less is known about COVID-19 outcomes across levels of disease control for these conditions. Methods: All adults aged ≥20...
9.
Zisman-Ilani Y, Khaikin S, Savoy M, Paranjape A, Rubin D, Jacob R, et al.
Ann Fam Med
. 2023 Feb;
21(2):112-118.
PMID: 36750357
Objective: The extent of shared decision making (SDM) use in the care of Black patients is limited. We explored preferences, needs, and challenges of Black patients to enhance SDM offerings....
10.
Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 - United States, January-July 2022
Boehmer T, Koumans E, Skillen E, Kappelman M, Carton T, Patel A, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Oct;
71(43):1359-1365.
PMID: 36301738
In December 2021 and early 2022, four medications received emergency use authorization (EUA) by the Food and Drug Administration for outpatient treatment of mild-to-moderate COVID-19 in patients who are at...